<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hemodialysis solutions: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hemodialysis solutions: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hemodialysis solutions: Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50354098"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bibag;</li>
<li>BiCart;</li>
<li>Centrisol;</li>
<li>CitraPure;</li>
<li>Citrasate;</li>
<li>CitriSol;</li>
<li>Diasol;</li>
<li>Dryasol;</li>
<li>GranuFlo;</li>
<li>NaturaLyte;</li>
<li>RenalPure;</li>
<li>Renasol;</li>
<li>Solcart B;</li>
<li>SteriLyte</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50354101"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Dialysis Solution</li></ul></div>
<div class="block dosfc drugH1Div" id="F50354107"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">The dialysate solution used for an intermittent hemodialysis session is uniquely created for each patient and ultimately based on mixing 3 components: acid concentrate, sodium bicarbonate concentrate (ie, the base), and purified water. In the US, water used in dialysate should meet or exceed standards set forth by the International Organization for Standardization (ISO), and subsequently adopted by the American National Standards Institute (ANSI) in collaboration with the Association for the Advancement of Medical Instrumentation (AAMI).</p>
<p style="text-indent:-2em;margin-left:2em;">Acid concentrate and sodium bicarbonate concentrate products should be mixed only in the dilution (ie, proportioning ratio) specified (eg, 35X, 36.83X, 45X) and used only in the type of hemodialysis machine/system specifically recommended by the manufacturer. In addition, some acid concentrate products and sodium bicarbonate concentrate products should only be used in conjunction with those specifically recommended as compatible by the manufacturer. Consult specific manufacturer’s product information for all compatibility recommendations.</p></div>
<div class="block foc drugH1Div" id="F243012"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:-2em;margin-left:2em;">Acid Concentrate:</p>
<p style="text-indent:-2em;margin-left:4em;">Liquid:</p>
<p style="text-indent:-2em;margin-left:6em;">Centrisol-Part A: Sodium 137 mEq/L, Potassium 0 to 4 mEq/L, Calcium 0 to 3 mEq/L, Magnesium 0.75 mEq/L, Chloride 100.75 to 107.75 mEq/L, Acetate 4 to 5 mEq/L, Dextrose 100 to 200 mg/dL, Bicarbonate 32 to 33 mEq/L [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Centrisol 100 Dextrose-Part A: Sodium 137 mEq/L, Potassium 0 to 3 mEq/L, Calcium 0 to 2.5 mEq/L, Magnesium 0.75 mEq/L, Chloride 100.75 to 106 mEq/L, Acetate 4 to 5 mEq/L, Dextrose 100 mg/dL, Bicarbonate 32 to 33 mEq/L [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">CitraPure: Sodium 137 mEq/L, Potassium 1 to 3 mEq/L, Calcium 2 to 3 mEq/L, Magnesium 1 mEq/L, Citric acid 2.4 mEq/L, Dextrose 100 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Citrasate: Sodium 100.3 mEq/L, Potassium 1 to 3 mEq/L, Calcium 2.5 mEq/L, Magnesium 1 mEq/L, Chloride 104.50 to 106.5 mEq/L, Acetate 0.3 mEq/L, Dextrose 100 mg/dL, Citrate 2.4 mEq/L [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">CitriSol: Sodium 80 to 100 mEq/L, Potassium 0 to 4 mEq/L, Calcium 0 to 2.5 mEq/L, Magnesium 1 mEq/L, Dextrose 100 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 35X, 36.83X, and 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Diasol: Sodium 80 to 100 mEq/L, Potassium 0 to 4 mEq/L, Calcium 0 to 3.5 mEq/L, Magnesium 0.70 to 1 mEq/L, Dextrose 100 to 200 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 35X, 36.83X, and 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">NaturaLyte: Sodium 100 mEq/L, Potassium 0 to 4 mEq/L, Calcium 0 to 3.5 mEq/L, Magnesium 1 mEq/L, Chloride 102 to 107.25 mEq/L, Acetate 4 mEq/L, Dextrose 100 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">NaturaLyte-4000 Series: Sodium 100 mEq/L, Potassium 0 to 4 mEq/L, Calcium 0 to 3.5 mEq/L, Magnesium 1 mEq/L, Chloride 102 to 107.25 mEq/L, Acetate 4 mEq/L, Dextrose 100 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">RenalPure: Sodium 137 mEq/L, Potassium 0 to 3 mEq/L, Calcium 0 to 3 mEq/L, Magnesium 0.75 mEq/L, Chloride 104 to 106 mEq/L, Acetic acid 4 mEq/L, Dextrose 100 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Renasol-Part A: Sodium 139 to 143 mEq/L, Potassium 0 to 3 mEq/L, Calcium 0 to 3.5 mEq/L, Magnesium 0.75 to 1.5 mEq/L, Chloride 101 to 110.25 mEq/L, Acetate 4 to 4.5 mEq/L, Dextrose 200 to 250 mg/dL, Bicarbonate 34.5 to 35 mEq/L [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 36.83X]</p>
<p style="text-indent:-2em;margin-left:6em;">Renasol 100 Dextrose – Part A: Sodium 140 mEq/L, Potassium 2 mEq/L, Calcium 2.5 mEq/L, Magnesium 0.5 mEq/L, Chloride 106 mEq/L, Acetate 4 mEq/L, Dextrose 100 mg/dL, Bicarbonate 35 mEq/L [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 36.83X]</p>
<p style="text-indent:-2em;margin-left:4em;">Powder:</p>
<p style="text-indent:-2em;margin-left:6em;">Citrasate Dry: Sodium 100.3 mEq/L, Potassium 1 to 3 mEq/L, Calcium 2.25 to 3 mEq/L, Magnesium 1 mEq/L, Chloride 104.25 to 107 mEq/L, Acetate 0.3 mEq/L, Dextrose 100 mg/dL, Citrate 2.4 mEq/L [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">CitriSol: Sodium 80 to 100 mEq/L, Potassium 0 to 4 mEq/L, Calcium 0 to 2.5 mEq/L, Magnesium 1 mEq/L, Dextrose 100 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 35X, 36.83X, and 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Dri-Sate: Sodium 137 mEq/L, Potassium 2 mEq/L, Calcium 2 to 2.5 mEq/L, Magnesium 0.75 mEq/L, Chloride 105 to 106 mEq/L, Acetic acid 4 mEq/L, Dextrose 100 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Dryasol: Sodium 80 to 100 mEq/L, Potassium 0 to 4 mEq/L, Calcium 0 to 3.5 mEq/L, Magnesium 0.70 to 1 mEq/L, Dextrose 100 to 200 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 35X, 36.83X, and 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">GranuFlo – 2400 Series: Sodium 100 mEq/L, Potassium 1 to 3 mEq/L, Calcium 2 to 3 mEq/L, Magnesium 1 mEq/L, Chloride 100.5 to 103 mEq/L, Acetate 8 mEq/L, Dextrose 100 mg/dL [strength represents amount after recommended dilution; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:2em;">Bicarbonate Concentrate:</p>
<p style="text-indent:-2em;margin-left:4em;">Liquid:</p>
<p style="text-indent:-2em;margin-left:6em;">Centrisol-Part B: [formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Renasol-Part B: [formulations available for use with proportioning ratio: 36.83X]</p>
<p style="text-indent:-2em;margin-left:6em;">SteriLyte: Sodium 37 mEq/L, Bicarbonate 37 mEq/L [strength represents final dialysate electrolyte yield; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:4em;">Powder:</p>
<p style="text-indent:-2em;margin-left:6em;">Bibag: (650 g, 900 g) [formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Centrisol-Part B: [formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">NaturaLyte-4000 Series: Sodium 37 mEq/L, Bicarbonate 37 mEq/L [strength represents final dialysate electrolyte yield; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">RenalPure: Sodium 37 mEq/L, Bicarbonate 37 mEq/L [strength represents final dialysate electrolyte yield; formulations available for use with proportioning ratio: 45X]</p>
<p style="text-indent:-2em;margin-left:6em;">Renasol-Part B: [formulations available for use with proportioning ratio: 36.83X]</p>
<p style="text-indent:-2em;margin-left:4em;">Powder Cartridge:</p>
<p style="text-indent:-2em;margin-left:6em;">Solcart B: (650 g, 760 g, 1100 g)</p>
<p style="text-indent:-2em;margin-left:6em;">BiCart: (720 g, 1250 g) [formulations available for use with proportioning ratio: 35 X, 45X]</p></div>
<div class="block use drugH1Div" id="F50354102"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">For use in a dialyzer during conventional, intermittent hemodialysis sessions to remove toxins and extra fluid from the body, and help regulate electrolytes and acid-base balance in patients in severe kidney failure or with end-stage kidney disease.</p></div>
<div class="block mst drugH1Div" id="F50354100"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes hemodialysis solutions among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Acid concentrate dialysate products may contain acetate, citrate, and/or acetic acid which can be converted in the body to bicarbonate. Dosing errors have occurred when practitioners have failed to consider the contribution of these substances to the patient’s overall bicarbonate levels. This oversight may lead to metabolic alkalosis in hemodialysis patients, which is a significant risk factor associated with cardiopulmonary arrest, hypotension, hypokalemia, hypoxemia, hypercapnia, and cardiac arrhythmia.</p>
<p style="text-indent:-2em;margin-left:4em;">The presence and quantity of acetate, citrate, and/or acetic acid vary by formulation and manufacturer; specific product labeling should be reviewed. Practitioners should always be aware that preexisting metabolic alkalosis (pre-dialysis serum bicarbonate levels ≥27 mEq/L) have been associated with an increased risk of mortality in hemodialysis patients.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50354106"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58844462"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Haemodialysis Acid 35X Formulation (F-1) | Haemodialysis Acid 45X Formulation (C-1) | Haemodialysis Acid 45X Formulation (C-2) | Haemodialysis Acid 45X Formulation (C-3) | Haemodialysis Acid Concentrate (Formula QPF-16) | Haemodialysis Acid Concentrate Formula (QPC-1) | Haemodialysis Acid Concentrate Formula (QPC-2) | Haemodialysis Acid Concentrate Formula (QPF-1) | Haemodialysis Acid Concentrate Formula (QPF-10) | Haemodialysis Acid Concentrate Formula (QPF-11) | Haemodialysis Acid Concentrate Formula (QPF-12) | Haemodialysis Acid Concentrate Formula (QPF-13) | Haemodialysis Acid Concentrate Formula (QPF-14) | Haemodialysis Acid Concentrate Formula (QPF-4) | Haemodialysis Acid Concentrate Formula (QPF-7) | Haemodialysis Acid Concentrate Formula (QPF-8) | Haemodialysis Acid Concentrate X35 Formula (QPF-2) | Haemodialysis Acid Concentrate X35 Formula (QPF-3) | Haemodialysis Acid Concentrate X35 Formula (QPF-5) | Haemodialysis Acid Concentrate X35 Formula (QPF-6) | Haemodialysis Acid Concentrate X35 Formula (QPF-9) | Haemodialysis Acid Concentrate X45 Formula (QPC-3) | Haemodialysis Acid Concentrate-Citrate Formula (QPK-1) | Haemodialysis Acid Concentrate-Citrate Formula (QPK-2) | Haemodialysis Acid Concentrate-Citrate Formula (QPK-3) | Sodium Bicarbonate Powder (PSI)</span></li></ul></div>
</div>
</div>
</div>
</div><div id="topicVersionRevision">Topic 113930 Version 20.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
